肥胖降低原发性痛风患者的降尿酸疗效:一项前瞻性队列研究
该前瞻性研究纳入633例男性痛风患者,按BMI分为正常体重、超重和肥胖组,并匹配基线年龄、病程和血尿酸水平,所有患者接受非布司他12周治疗(剂量从每日20 mg增至40 mg)。结果显示,肥胖组达到血尿酸<6.0 mg/dl的比例为38.9%,显著低于超重组(54.2%)和正常体重组(63.8%),高BMI独立阻碍血尿酸达标(HR=0.92,95%CI 0.89-0.96,P<0.001)。结论认为肥胖(而非超重)显著降低男性痛风患者基于非布司他的降尿酸治疗疗效。
要点
- 肥胖组第12周血尿酸<6.0 mg/dl达标率为38.9%,低于超重组54.2%和正常体重组63.8%(P<0.05)。
- 高BMI独立阻碍血尿酸达标(HR=0.92,95%CI 0.89-0.96,P<0.001),匹配后效应相似。
- 肥胖和超重组痛风发作累积发生率高于正常体重组(P<0.05)。
核心结论
- 肥胖显著降低男性痛风患者基于非布司他的降尿酸治疗疗效,而超重则不然。
研究设计与样本
- 前瞻性研究纳入633例男性痛风患者,按BMI分为正常体重、超重和肥胖组,并同时匹配基线年龄、病程和血尿酸水平。
- 所有参与者接受非布司他治疗12周,剂量从每日20 mg增至40 mg。
主要发现
- 第12周时,肥胖组达到血尿酸<6.0 mg/dl的比例为38.9%,显著低于超重组的54.2%和正常体重组的63.8%(P<0.05),超重组与正常体重组之间无显著差异。
- 高BMI独立阻碍血尿酸达标(HR=0.92,95%CI 0.89-0.96,P<0.001),匹配后效应相似。
- 肥胖和超重个体痛风发作累积发生率高于正常体重组(P<0.05)。
- 限制性立方样条提示BMI与血尿酸达标风险比之间呈线性关系(非线性P>0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Obesity affects 53% of gout patients, while its effect on urate-lowering therapy (ULT) is unclear. This study aimed to compare the response to febuxostat among different BMI catalogs of male gout patients. METHODS: A prospective study recruited 633 men with gout, classified by BMI into normal-weight, overweight and obese groups. Baseline age, disease duration and serum urate (SU) levels were matched simultaneously. All participants received febuxostat for 12 weeks, increasing the dosage from 20 to 40 mg daily. We compared the efficacy of ULT and the incidence of gout flares in three groups. Cox regression analysis was used to identify risk factors for achieving target SU levels before and after matching. Restricted cubic spline (RCS) curves were used to illustrate the relationship between BMI and hazard ratio (HR) for SU achievement. RESULTS: The proportion of participants achieving SU < 6.0 mg/dl in the obese group was 38.9%, significantly lower than the overweight (54.2%) and normal-weight groups (63.8%) (P < 0.05), with no significant difference between the overweight and normal-weight groups at week 12. High BMI (HR = 0.92, 95% CI 0.89-0.96, P < 0.001) independently prevented achieving the SU target, with a similar effect after matching. Obese and overweight individuals had a higher cumulative incidence of gout flares compared with the normal-weight group (P < 0.05). The linear relationship between BMI and HR for achieving the SU target was suggested by RCS (nonlinear P > 0.05). CONCLUSION: Obesity significantly reduces the efficacy of febuxostat-based ULT in male gout patients rather than being overweight. TRIAL REGISTRATION: China Clinical Trial Registry, #ChiCTR2300078804.
引用
- Cheng Z, Xu X, Qi H, et al. Obesity reduces the urate-lowering efficacy among patients with primary gout: a prospective cohort study. Rheumatology (Oxford). 2025. PMID: 39928353. doi:10.1093/rheumatology/keaf076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。